{
  "nctrialId": "HC-2101",
  "title": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of IBS-225 (serotonin modulator) in Patients With Atopic Dermatitis",
  "officialTitle": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of IBS-225 (serotonin modulator) in Patients With Atopic Dermatitis",
  "sponsor": "Alberta Health Services",
  "indication": "Atopic Dermatitis",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-2101.json",
  "fileSize": 203856,
  "date": "2023-07-11",
  "completionDate": "2027-11-18",
  "drugName": "IBS-225 (serotonin modulator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a randomized double-blind, active-controlled multi-center study designed to evaluate the efficacy and safety of IBS-225 (serotonin modulator) in patients with Atopic Dermatitis. The study will enroll approximately 259 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-81 years\n- Confirmed diagnosis of Atopic Dermatitis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}